The weekly brief · free to read, free to cite
Flu Codes, Fee Schedule Proposals, and a Rate Reset Line Up for RCM Teams
Week of July 13–19, 2026
This week's review spans a broad slate of federal publications touching physician payment policy, seasonal vaccine coding, drug approvals, coding infrastructure, and overpayment interest rates. Five items surfaced from the scan, none tied to a specific MAC, but collectively touching a meaningful swath of procedure codes that billing operations will need to track as effective dates approach.
CLV Intelligence™ reviewed 103 publications across all 16 Medicare Administrative Contractor jurisdictions this week. 5 are covered below. Every item links its primary government source.
Lead item
Federal Register Proposed Rule: Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program
- Jurisdiction
- National
- Specialty
- Physician Fee Schedule
- Type
- proposed_rule
- Effective
- Not announced
A national rulemaking of this scope typically reshapes payment methodology and coverage policy across Part B, with downstream effects on Shared Savings Program participants and drug rebate calculations. The scale of change here means billing and coding teams tied to physician fee schedule logic have a rulemaking cycle to watch closely.
Item 2
CMS Transmittal R13859CP: Influenza Vaccine Payment Allowances - Annual Update for 2026-2027 Season
- Jurisdiction
- National
- Specialty
- Multi-specialty
- Type
- fee_schedule
- Effective
- August 17, 2026
Twenty-two vaccine and administration codes are refreshed for the coming flu season, landing squarely on any practice or lab billing seasonal immunizations. The runway before the new allowances take hold is short enough that claims submitted on old rates risk mismatch.
Codes:9065390654906559065690657906589066190662906739067490682906859068690687906889068990694Q2035Q2036Q2037Q2038Q2039
Item 3
FDA Approval: SARCLISA ESCENA (ISATUXIMAB-IRFC) — Type 3 - New Dosage Form
- Jurisdiction
- National
- Specialty
- Hematology
- Type
- billing_update
- Effective
- July 9, 2026
A new dosage form approval for an existing hematology therapy changes how claims for this product get built, with exposure concentrated in infusion centers and specialty pharmacies handling multiple myeloma treatment billing.
Item 4
CMS Transmittal R13867CP: File Conversions Related to the Spanish Translation of the Healthcare Common Procedure Coding…
- Jurisdiction
- National
- Specialty
- Multi-specialty
- Type
- billing_update
- Effective
- October 5, 2026
Infrastructure changes to how coding files are translated and converted carry indirect but real exposure for any organization serving Spanish-language patient populations or relying on multilingual coding references in claims workflows.
Item 5
CMS Transmittal R13869FM: Notice of New Interest Rate for Medicare Overpayments and Underpayments -4th Quarter…
- Jurisdiction
- National
- Specialty
- Multi-specialty
- Type
- billing_update
- Effective
- July 21, 2026
A quarterly interest rate reset on Medicare overpayments and underpayments lands on finance and compliance teams managing recoupment timelines, with the new rate taking effect on a short runway that leaves little room for recalculation delays.
Taken together, the week's publications span policy, product, and process — a reminder that reimbursement exposure rarely arrives from a single direction. Billing leaders reviewing this slate should weigh runway against complexity on each item independently.
See what changed in your jurisdiction
This brief covers the week. The free 90-day snapshot covers your specialty and your MAC — every policy change on record, with its source.
CLV Intelligence monitors and summarizes publicly available federal and MAC publications. It is not legal, medical, billing, or coding advice.